850421-08-8

Usage

Uses

Used in Organic Synthesis:
1-(5-bromo-3-chloropyrazin-2-yl)hydrazine is used as a synthetic building block for creating a variety of complex organic molecules. The presence of bromine and chlorine atoms allows for selective functionalization and further chemical modifications, making it a versatile compound in the field of organic synthesis.
Used in Medicinal Chemistry:
In the pharmaceutical industry, 1-(5-bromo-3-chloropyrazin-2-yl)hydrazine is used as a key intermediate in the development of new drugs. Its unique structure and reactivity can be exploited to design and synthesize bioactive molecules with potential therapeutic applications.
Used in Chemical Research:
1-(5-bromo-3-chloropyrazin-2-yl)hydrazine serves as a valuable research tool in understanding the fundamental chemical properties and reactivity patterns of heterocyclic compounds. It can be employed in academic and industrial research settings to explore novel reaction mechanisms and develop innovative synthetic strategies.
Used in Material Science:
1-(5-broMo-3-chloropyrazin-2-yl)hydrazine may also find applications in material science, where its specific properties can be utilized to create new materials with tailored characteristics. For instance, its reactivity with other molecules could be exploited to develop novel polymers or coatings with specific functionalities.

Upstream product

• 850421-07-7 N'-(5-bromo-3-chloropyrazin-2-yl)-2,2,2-trifluoroacetohydrazide 

Downstream Products

• 1610045-39-0 6-bromo-8-chloro-3-methyl-[1,2,4]triazolo[4,3-a]pyrazine 
• 1334135-75-9 6-bromo-8-chloro-[1,2,4]triazolo[4,3-a]pyrazine 

Relevant academic research and scientific papers

COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA

The present invention relates to the use of volasertib, or a pharmaceutically acceptable salt thereof or a hydrate thereof, in combination with a BET inhibitor, or a pharmaceutically acceptable salt thereof or a hydrate thereof for treating patients suffering from acute myeloid leukemia (AML).

COMPOUNDS AND METHODS FOR THE MODULATION OF AhR

Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formula: (I) wherein the letters and symbols a, b, c, d, e, f, A, R1, X1, Ar1 and Ar2 have the meanings provided in the specification.

TRIAZOLOPYRAZINONES AS PDE1 INHIBITORS

The present invention provides triazolopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

Triazolopyrazine

The present invention encompasses compounds of general formula (I) wherein the groups R1 to R3, X3 to X6 have the meanings given in the claims and in the specification. The compounds of the invention are suitabl

TRIAZOLOPYRAZINE DERIVATIVES AS BRD4 INHIBITORS

The present invention encompasses compounds of general formula (I), wherein the groups R1 to R3, X3 to X6 have the meanings given in the claims and in the specification. The compounds of the invention are suitab

TRIAZOLOPYRAZINE

Disclosed are compounds of the formula (I) wherein the groups R1 to R3 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.

HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE

The present invention relates to compounds and methods which may be useful as inhibitors of H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

SUBSTITUTED 2H-[1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS GSK-3 INHIBITORS

The invention relates to compounds of formula (I) prodrugs thereof, and the pahrmaceutically acceptabel salts of the compounds and prodrugs, wherein Ra, Rb, R1 and R2 are as defined herein; pharmaceutical compositions thereof; and uses thereof.